VidhiAagaz
International Journal ofLaw Management & Humanities
ISSN 2581-5369 · Open access
International Journal ofLaw Management & Humanities
Open accessArticleVol. 3 No. V (2020)pp. 1307–1330

Issues Challenges of Patentability of Generic Drugs in India

View PDF
9views0downloads
Published 12 November 2020 · pp. 1307–1330 · Vol. 3 No. V (2020)
Abstract

Generic drugs are the same as those already approved in the dosage type, safety, strength, path, consistency and performance characteristics of an already approved brand name medication. Only after a thorough review by FDA and after a certain period of time the generic drugs be available, the brand name version is exclusively on the market. This is because new drugs are generally protected by patents, like all new goods and the emerging pharmaceutical R&D scenario in India has several constraints in the context of global models and approaches for new drugs from concept to market. India should give a thought on the growth and of the pharmaceutical market and on how to balance the cost of innovation in drug research and universal access to the fruits of this research.

Keywords
Generic drugsPatentabilitySection 3(d) Patents ActAccess to medicineBioequivalencePharmaceutical patents

How to cite

Sayani Chandra & Ritwika Mazumdar, Issues Challenges of Patentability of Generic Drugs in India, 3 Int'l J.L. Mgmt. & Human. 1307 (2020).

Cite this article

Sayani Chandra & Ritwika Mazumdar, Issues Challenges of Patentability of Generic Drugs in India, 3 Int'l J.L. Mgmt. & Human. 1307 (2020).
Chat with us